WHO calls for better science-based regulations for biosimilars

Home/Policies & Legislation | Posted 13/06/2014 post-comment0

The sixty-seventh World Health Assembly (WHA) of the World Health Organization (WHO) closed on 24 May 2014, after adopting more than 20 resolutions on public health issues of global importance, one of which calls for better science-based regulations for biosimilars.

Regulation V13H16

Resolution WHA67.21 on access to biotherapeutic products including similar biotherapeutic products and ensuring their quality, safety and efficacy, urges Member States:

  • To develop or strengthen national regulatory assessment and authorization frameworks, to meet the needs for biologicals, including biosimilars
  • To develop the necessary scientific expertise to facilitate development of solid, scientifically-based regulatory frameworks that promote access to products that are affordable, safe, efficacious and of high quality
  • To ensure that new national regulations do not create barriers to access to quality, safe, efficacious and affordable biologicals, including biosimilars

The resolution comes as a result of the fact that WHO acknowledges that biosimilars ‘could be more affordable and offer better access to treatments of biological origin, while ensuring quality, safety and efficacy’.

Generics and biosimilars advocate the European Generic medicines Association (EGA) welcomed WHO’s resolution on access to biologicals and biosimilars. EGA’s Director General, Mr Adrian van den Hoven, commented that ‘these resolutions constitute important milestones for patients worldwide as they aim to support national drug regulatory authorities, particularly in developing countries, to strengthen their regulatory systems, while promoting equitable access to quality, safe, efficacious, and affordable medical products.’

Related article

Global guidelines for biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: WHO

Related content
Public consultation for the modification of the biosimilars regulation
02 AA010638
Home/Policies & Legislation Posted 16/01/2024
COFEPRIS promotes regulatory cooperation in the Americas
Latin America 1638px
Home/Policies & Legislation Posted 12/12/2023
ANVISA's decision on 'Skinny labels' for generics pending
Labelling V14I26
Home/Policies & Legislation Posted 14/11/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010